Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system
- PMID: 32418864
- DOI: 10.1016/j.healun.2020.04.012
Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system
Abstract
Background: Chronic lung allograft dysfunction (CLAD) is a heterogeneous condition. Characterization of CLAD phenotypes is essential to enhance the understanding of pathogenesis and guide new therapies. The study objective was to validate the new International Society for Heart and Lung Transplantation (ISHLT) CLAD classification system and further explore patients who do not fall into the defined CLAD sub-categories.
Methods: We performed a single-center, retrospective cohort study of adult, first, bilateral lung transplants performed from 2010 to 2015. Patients with CLAD were classified on the basis of the 2019 ISHLT consensus document. CLAD phenotypes and other potential predictors of survival after CLAD onset were assessed using Kaplan-Meier and Cox proportional hazards models.
Results: Among the 174 subjects with CLAD, 104 (59.8%) had bronchiolitis obliterans syndrome (BOS), 16 (9.2%) restrictive allograft syndrome (RAS), 9 (5.2%) mixed, and 19 (10.9%) undefined phenotype. A total of 26 patients (14.9%) did not match any of these 4 categories and remained unclassified. Allograft survival post-CLAD onset was longer for patients with BOS (median, 500 days) than patients with RAS (median, 372 days) or mixed (median, 328 days). The 45 patients (26.8%) with undefined/unclassified phenotype were combined and recategorized on the basis of the presence or absence of characteristic RAS-like opacities on chest imaging; those with RAS-like opacities had significantly worse allograft survival than patients with BOS (hazard ratio, 2.14; 95% confidence interval, 1.17-3.93; p = 0.014) and similar survival to RAS or mixed phenotype.
Conclusions: The new ISHLT CLAD phenotype classification is informative with regards to post-CLAD outcomes. Chest imaging demonstrating persistent parenchymal or pleural fibrosis may be used for risk-stratification of patients who do not match the major CLAD phenotypes.
Keywords: bronchiolitis obliterans syndrome; chronic lung allograft dysfunction phenotypes; lung transplant; mixed phenotype; restrictive allograft syndrome.
Copyright © 2020. Published by Elsevier Inc.
Comment in
-
Putting the 2019 CLAD consensus definitions to the test: Two steps forward, one step back?J Heart Lung Transplant. 2020 Aug;39(8):771-773. doi: 10.1016/j.healun.2020.06.008. Epub 2020 Jun 20. J Heart Lung Transplant. 2020. PMID: 32620449 No abstract available.
Similar articles
-
Validation of a post-transplant chronic lung allograft dysfunction classification system.J Heart Lung Transplant. 2019 Feb;38(2):166-173. doi: 10.1016/j.healun.2018.09.020. Epub 2018 Oct 4. J Heart Lung Transplant. 2019. PMID: 30391199
-
Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.J Heart Lung Transplant. 2011 Jul;30(7):735-42. doi: 10.1016/j.healun.2011.01.712. Epub 2011 Mar 17. J Heart Lung Transplant. 2011. PMID: 21419659
-
Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction.J Heart Lung Transplant. 2023 Aug;42(8):1152-1160. doi: 10.1016/j.healun.2023.03.009. Epub 2023 Mar 23. J Heart Lung Transplant. 2023. PMID: 36963446
-
Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS).Semin Respir Crit Care Med. 2013 Jun;34(3):352-60. doi: 10.1055/s-0033-1348463. Epub 2013 Jul 2. Semin Respir Crit Care Med. 2013. PMID: 23821509 Review.
-
Chronic Lung Allograft Dysfunction.Thorac Surg Clin. 2022 May;32(2):231-242. doi: 10.1016/j.thorsurg.2021.11.004. Thorac Surg Clin. 2022. PMID: 35512941 Review.
Cited by
-
Utility of bile acids in large airway bronchial wash versus bronchoalveolar lavage as biomarkers of microaspiration in lung transplant recipients: a retrospective cohort study.Respir Res. 2022 Aug 26;23(1):219. doi: 10.1186/s12931-022-02131-5. Respir Res. 2022. PMID: 36028826 Free PMC article.
-
Oesophageal stasis is a risk factor for chronic lung allograft dysfunction and allograft failure in lung transplant recipients.ERJ Open Res. 2023 Sep 10;9(5):00222-2023. doi: 10.1183/23120541.00222-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37817870 Free PMC article.
-
[Fibrotic remodeling of the lung following lung and stem-cell transplantation].Pathologe. 2021 Feb;42(1):17-24. doi: 10.1007/s00292-020-00898-2. Epub 2021 Jan 8. Pathologe. 2021. PMID: 33416936 Review. German.
-
The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Recipients with Chronic Rejection.Am J Respir Crit Care Med. 2024 Jun 1;209(11):1360-1375. doi: 10.1164/rccm.202308-1326OC. Am J Respir Crit Care Med. 2024. PMID: 38271553 Free PMC article.
-
Transition from BOS to RAS impairs prognosis after lung transplantation-CLAD subtype analysis by CT volumetry.PLoS One. 2022 Oct 12;17(10):e0275563. doi: 10.1371/journal.pone.0275563. eCollection 2022. PLoS One. 2022. PMID: 36223371 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources